Improving identification and treatment of atrial fibrillation

Practitioner

Volumn 256, Issue 1756, 2012, Pages 27-31

  Betts, Tim R ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT REFERRAL; RISK FACTOR;

ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; HUMANS; REFERRAL AND CONSULTATION; RISK FACTORS; STROKE;

EID: 84872252416     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. National Institute for Health and Clinical Excellence. CG36. The management of atrial fibrillation. NICE. London. 2006
2. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2009 ;285(22):2864-2870
3. Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137(2):263-72
4. Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP-AF) http://www.improvement.nhs.uk/graspaf/
5. Pisters R, Lane DA, Nieuwlaat R et al. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; 138(5):1093-100
6. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;159:677-85
7. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet2007;370 (9586): 493-503
8. National Institute for Health and Clinical Excellence. TA249. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation NICE. London.
9. National Institute for Health and Clinical Excellence. TA256. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE. London. 2012
10. Holmes DR, Reddy VY, Turi ZG et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet2009;374(9689):534-42
11. National Institute for Health and Clinical Excellence. IPG168. Percutaneous radiofrequency catheter ablation for atrial fibrillation. NICE. London. 2006